Momenta Pharmaceuticals Profile

14.25
USD 0.1  0.7%
12.35Last Month High 19.05 
14.2Trading Day  High 14.4 

Exercise or conversion by Craig Wheeler of 25667 shares of Momenta Pharmaceuticals subject to Rule 16b-3

Momenta Pharmaceuticals Inc insider trading alert for exercise of stock option (right to buy) by Craig Wheeler, President, on October 2, 2017. This event was filed by Momenta Pharmaceuticals I with SEC on 2017-10-02. Statement of changes in beneficial ownership - SEC Form 4. Craig Wheeler is currently serves as ceo and president and executive director of Momenta Pharmaceuticals [view details]   

Momenta Pharmaceuticals Summary

Momenta Pharmaceuticals Inc (MNTA) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 258 people. Momenta Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 983.37 M. Momenta Pharmaceuticals Inc conducts business under Healthcare sector and is part of Drugs - Generic industry. This company has 76.23 M outstanding shares of which 4.63 M shares are now shorted by private and institutional investors with about 9.13 trading days to cover. MOMENTA PHARMA currently holds about 446.55 M in cash with 55.04 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.03.
Check Momenta Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Momenta Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Momenta Pharmaceuticals Against Markets

Current Ratings  

Momenta Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
< 64% 
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameMomenta Pharmaceuticals Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationMASSACHUSETTS, U.S.A
Business Address675 West Kendall Street, Cambridge, MA 02142, United States
ExchangeNASDAQ
CIK Number01235010.0
CUSIP60877T100
SectorHealthcare
IndustryDrugs - Generic
BenchmarkDOW
Websitewww.momentapharma.com
Contact Number617 621 0431
CurrencyUSD - US Dollar

Did you try this?

Run Volatility Analysis Now
   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
Hide  View All  Next  Launch Volatility Analysis

Recommendations

Momenta Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
17.75Buy8Odds
Momenta Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Momenta Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Momenta Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.23February 21, 2017
Momenta Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate